Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry you didn't give the baby a chance to grow, that is what makes the stock markets interesting, you held CYGX so long I thought you may want to get in on these two ground floor technologies, with no competition. VNTH and CTSO are still my best stocks I hold . Good luck
Paulness, I sold vnth taking a big hit, bad timing perhaps. It is not for me right now as it goes against my resolve to eliminate losses. As our "taste" in stocks is so similar, perhaps it is best right now not to recommend anything more as it acts as too much of an "enticement" for me. Thanks. Best regards, Holycow
holycow, if you have a little time listen to Cytosorbents presentation was very well done and a major market they are cornering .Don't forget to use the arrow on the top of the page to change the slides
http://wsw.com/webcast/needham65/ctso/
Come over to the VNTH board would like to have you as one of the posters ,also you can learn a lot over there , a good honest poster like yourself is always welcome . good luck from Paul.
Paulness, interesting about first of many cancers. I know VOCs (Volatile Organic Compounds) from the creation of ozone air pollution. Ozone is three atoms of oxygen rather than two and it gets the third atom from combustion, the burning of hydrocarbons, fossil fuels. VOCs fits here somewhere but I don't understand it exactly.
Good to hear from you , sad about the person with lung cancer, It seems that every type of cancer in the body has its own VOCs , lung cancer is the first one that will be done ,breast ,pancreas ,liver, cancers are next, the health industry are going to love this sensor .
Paulness, I bought some vnth (Vantage). I read about the app for the breathalizer to detect VOCs (Volatile Organic Compounds) linked with lung cancer that can be attached to a smart phone (working on it) and it sounds clever. Lung cancer is a big killer and, because there are few symptoms, they find it too late when there is basically nothing they can do. My friend's wife has it, poor girl, (in her 50s) and all they can really do is to monitor it. She was a smoker but I will refrain from saying, of what. Nice to be in contact with you. Holycow
Thanks for your reply , these two are my golden tickets I felt you should know and maybe prosper with these two stocks,VNTH ,CTSO. hope all is well.
Hey Paulness, I only read occasionally now. I have cooled considerably to penny stocks and to the market in general even though my predictions of a market downturn have been wrong for some two years now and the market seems to just be going up up up. I do thank you for your advice which I still value and perhaps I will look into them. Holycow
I don't know if you are still reading this board, but my second best pick is CTSO Cytosorbents they are selling up a storm in the European unions , should be over 1.00 by years end that is a 300% gain on your money going for 23 cents now. best pick is VNTH
holycow if you want to read more about the Vantage health app read this!
http://www.nuviun.org/smartphones
I highly advise you holycow to take a position in VNTH, read about it, a 100,000 share position now will cost you about 14 thousand dollars, the market for the sensor App for the healthcare industry is staggering ,VNTH could be 3 dollars a share by years end if not much more .
http://www.vantagehealthinc.com/#!about/c24sq
read everything on the site I provided , Good luck, go to the Ihub VNTH board and read all the post , I have great expectations that all stock holders of VNTH will be well off in 2 years ,the longs will be impressed. Of all the stocks I own this one is the best. Hope you and yours are feeling well ,and all the CYGX family.Good luck
Did you ever look at PVCT Provectus read about it, looks like a very good one, I think I talked about it about 2 years ago , very interesting patented technology . Good luck.
don't follow my mistake. eom
It's too bad that the people involved in bringing back CYGX couldn't make a update to let us know what to do . Things do take time,
Do you think I should claim a loss now, or hang in there until next year's tax filing? I mean, miracles do happen.
Those working in the shadows to bring this about..
..could not come to an agreement over how to divide the corpse.
Keep an eye on VNTH the NASA phone app that will change how people are diagnosed, the breath holds the keys to your ailments.Also a stock that I had for years when absolutley nuts PVCT .
Paulness, I see ctso more than doubled since I found out about it. I am quite shocked. I don't own it, withdrawing now from "equities" after more losses. Best of luck though. You come up with interesting picks.
holycow, if you want to get into this company Vantage Health they are in the middle of making the first Tricorder, stock symbol VNTH they are only .12 cents a share and 80 % is held by insiders and no one is selling. Nanobeak is the parent company . Big news with NASA read and Good luck . I got into this one also very big
http://www.parabolicarc.com/2014/01/07/vantage-health/#more-51269
We’re very pleased to have Ames inventiveness recognized with this award for the third consecutive year,” said S. Pete Worden, NASA Ames center director. “With this invention, our people have basically created the insides of a tricorder, and based on the uses we’ve already demonstrated, I can’t wait to see the fantastic applications that NASA and industry are going to devise for it.”
Around the first of April of last year (nearly 10 months ago), we were told CYGX was getting off the ground again. Since then, there has been very little publicity about the turn-around. Does ANYONE know ANYTHING to give us any hope? Any info would be most appreciated!
bird flu stories on drudge this morning. We had the right focus. Too bad it didn't work out.
Merry Christmas to all the CYGX family of stockholders ,may the coming year bring us all prosperity and good health.
You can remove MEDS off your watch list it got bought out for $1.35 a share had high hopes for it, made some money on this one, but had wished for a lot more.
exciting paulness. You have a vision. I hope you hit it big, nano nano. Holycow
A big ten four on celebrating Christmas , Very excited about NNAN naturalnano the Halloysite nanotubes can be used as a filter to trap tumor cells,that is what excited me because the cancer \tumor\sepsis filter industry is taking off big and I invested in AEMD , CTSO and now NNAN just to cover my basis in this field plus NNAN Halloysite nanotubes can be used in the body armor industry, we all know how big that is.I bought big in NNAN 1.2 million at.0044 , will add if it goes down below that .
http://www.naturalnano.com/index.php?option=com_content&task=view&id=203&Itemid=39
Paulness, thanks for latest stock tip. I put it on my watch list. Best wishes to you for a merry Christmas if you celebrate that one and good health and much success for the year 2014 ahead.
Hi holycow I found NNAN last week been looking and I jumped in big, NaturalNano just got the Patent on Halloysite nanotubes that looks to be the big thing in the next 5 years little under a penny has 300 million shares out and lots of news in the works take a look a 100,000 shares will cost you 800 dollars could go to dollar land , just to let you know , If I don't hear from you have a great Christmas and a great new year.
http://www.naturalnano.com/
PS I sold all of my INO that you gave me and bought as much NNAN as I could .
Happy holiday weekend to you too Paulness. Call yourself Paul however many times you want but to me, it is always Paulness. A quality involving dogged optimism, unwillingness to give up and hope for the future. May we hear something positive about the stock having "risen" during 2014.
Nice article ,hope you have a happy Thanksgiving and all Cytogenix shareholders have a great holiday. from Paul
RNAi, an alternative gene silencing technology to ssDNA, is being used? in an experiment for Parkinsin's. I haven't read the article but I link it below.
Will we see the company come back and start trading again? I figure they are working toward that goal. After all, I am feeling hungry for a good slice of pizza.
http://www.nih.gov/news/health/nov2013/ninds-24.htm
I believe you are wrong in that assessment. The real culprit stole CYGX's intellectual properties with some slick legal maneuvers and that's what killed the company.
I see from your research that the Nelkin family has millions of shares that I assume were payments for services rendered. What I dont see is shares sold numbers and perhaps that is not public knowledge.I see the pump but not the dump but what you say makes sense and I will dig for more proof.
Any news in Cytogenix land , if anyone heard anything new please give a post , we need some news here.
Doug Nelkin? That's rich.
The stockholder and person from CT issued hundreds of thousands of shares as a 'Cytogenix' finder ?
The person (and family) repeatedly pointed out as the party behind a number of the pump & dump PR's issued by the company or at least in its name ?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=27455619
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=32095180
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=27475025
I have sent these postings and the past research onto the SEC.
Good luck Doug.
correction. The protein that serves as a red flag for the immune system to engulf and then attack and destroy parts of the brain is called C1q (small q, but I even got the letter wrong based on a faulty recollection, we humans being so fallible).
gdepc, thanks. Will the day soon come when we will be back in the action? Right now, I have been looking into this new idea about Alzheimer's that it is from an attack of the immune system on the person's own brain, Attack and destroy - leaving people with pieces of their brains gone, gone. There is a red flag that attaches to parts of the brain that says to the immune system: "eat me". Then the attack begins. The protein is called C1P. So many things to work on. Take care, holycow
About 4 months old, good read on Medistem MEDS
http://finance.yahoo.com/news/medistems-endometrial-regenerative-cell-erc-130000204.html
My coffee Plain no sugar LOL
paulness, fair enough. I will put MEDS on the watch list. HC. On a tangent, I was surprised that I ordered a hot chocolate at Starbucks and they wrote on the cup HC. I thought, "how did they know my handle, lol"
I have MEDS with a 1000 times more potential a even a lower float ,been collecting it when it was around 25 to 40 cent range put MEDS on your watch list, it is around 2 dollars now, but looks to be ready for a great run next year . Right now I am happy what I am holding. Thanks.
paulness, be careful with bthe as it could have peaked and might be on the way back down on this down day in general for the market. Not that I am good at reading the tea leaves.
paulness, info on BTHE Boston Therapeutics. You take a pill after eating and it reduces blood glucose, good for Type II Diabetes. An article below:
Boston Therapeutics Addressing Unmet Medical Needs by Harnessing Complex Carbohydrate Chemistry
MarketwiredPress Release: BioMedReports – Mon, Apr 22, 2013 7:01 AM EDT
Email
Print
RELATED CONTENT
RELATED QUOTES
Symbol Price Change
BTHE 1.40 +0.30
LOS ANGELES, CA--(Marketwired - Apr 22, 2013) - In a newly published Expert Briefing which appears at BioMedReports, David Platt, Ph.D., CEO of Manchester, NH-based Boston Therapeutics (OTCQB: BTHE), writes that Carbohydrates have been shown to play a fundamental role in normal cell functions as well as in major disease pathologies including cancer, cardiovascular disease and inflammatory diseases.
As a class of molecules, carbohydrates have an enormous range of shape, orientation and composition. Due to this structural diversity, carbohydrate chemistry can be applied to develop a broad range of complex therapeutic molecules and drugs, including pure carbohydrates as well as protein-linked carbohydrates, or glycoproteins. However, as a consequence of their structural complexity, carbohydrates have not received as much scientific attention as nucleic acids and proteins. However, significant progress is being made in this area.
Boston Therapeutics is developing a non-systemic, non-toxic chewable complex carbohydrate-based compound named PAZ320 for its ability to lower post-meal elevation of blood glucose, and thus as a treatment to delay or prevent the onset of Type 2 diabetes and related complications such as heart disease, stroke, kidney damage, retinopathy and diabetic foot. The compound is a complex polysaccharide to be taken before meals; it operates in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbs in foods during digestion, lowering the amount of available glucose absorbed via the intestine.
Researchers have written a paper, slated to be published in the peer-reviewed journal Endocrine Practice, reporting positive Phase II clinical trial results of PAZ320 in patients with Type 2 diabetes. The study evaluated the combination of PAZ320 and oral agents or insulin in 24 patients with Type 2 diabetes between the ages of 18 and 75 with a body mass index of 25-40 kg/m2 and with HbA1c of less than or equal to nine percent. HbA1c is a lab test that shows the average level of blood sugar (glucose) over the previous three months.
Forty-five percent of patients responded with a 40 percent reduction of post-meal glucose in the blood compared to baseline in a dose-dependent manner. Additionally, results showed the effect of PAZ320 does not correlate with duration of diabetes and works regardless of concurrent diabetes medications. There was no severe hypoglycemia and gastrointestinal side effects were mild. Satiety also was observed. There were no serious adverse events from the data analysis of the open-label dose escalation crossover trial on Type 2 diabetic patients.
In the briefing, Platt explains that a separate potential application of carbohydrate chemistry is as an injectable anti-necrosis drug, both for the prevention of necrosis and the treatment of ischemic conditions that may lead to necrosis. Boston Therapeutics is developing this application under the name IPOXYN™. The drug consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.
Necrosis is the outcome of severe and acute injury. It is involved in many pathological conditions such as heart attack, brain injuries and stroke, neurodegenerative diseases such as Alzheimer's dementia, Lou Gehrig's disease (ALS), septic shock, liver cirrhosis, chronic hepatitis, pancreatitis, diabetes, acute or critical limb ischemia, gangrene, chronic pressure ulcers and many others. Necrosis occurs following ischemia (a shortage of oxygen supply to the tissue due to restriction in blood supply). The only treatment available at present for necrosis is providing oxygen by a high pressure facility. Thus, there is a crucial need to develop drugs for prevention and treatment of this pathology.
For decades, oxygen carriers have been developed for perfusion and oxygenation of ischemic tissue; none have yet succeeded. These products were either blood-derived elements, synthetic perfluorocarbons or red blood cell modifiers. Several of the Hemoglobin-Based Oxygen Carriers (HBOC) contained nonfunctional methemoglobin impurities. These products failed to secure FDA approval based upon either poor outcomes in clinical trials or poorly formulated product.
The new approach to treatment of ischemic tissue and prevention of necrosis is fundamentally different; it is a New Chemical Entity (NCE), not a biologic blood substitute, with a modified Heme chemical structure.
In summary, the report points out that the complex carbohydrate chemistry, as it is being harnessed by Boston Therapeutics, is a key tool for addressing unmet medical needs in a variety of areas. Its continued development might offer new treatments and hope for millions of patients worldwide.
Disclosure: None
The complete version of this Expert Briefing can be found here:
http://www.biomedreports.com/20130422132199/addressing-unmet-medical-needs-by-harnessing-complex-carbohydrate-chemistry.html
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
Follow Us
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com
paulness, interesting about XNA but scary as well. Is a publicly traded company involved with it? Meanwhile, my broker who was going to try to help me get the shares back has now moved offices. There is still a chance he could help me though. May the new version of cytogenix get off the ground and start trading soon. One more thing paulness, BTHE is on a rip. My friend told me about it some 9 months ago. I am not getting involved personally because it has already gone up so much in the past few days that I fear I would get pummeled. My friend met the principal on a bus. Sorry that I forgot what they are working on but it sounded good. I thought you might like to check it out. Right now, I am in the process of pulling in my horns.
Followers
|
154
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
64738
|
Created
|
07/14/03
|
Type
|
Free
|
Moderators |
CytoGenix, Inc.
Phone: (830) 632-5944
Fax: (830) 632-5944
CytoGenix is a Nevada public corporation traded under the symbol CYGX.PK.
http://www.pr-inside.com/cytogenix-inc-to-become-sec-compliant-r2160873.htm
Email: info@cytogenix.com
Our Transfer Agent is Nevada Agency and Trust Company. Shareholders of record with questions about lost certificates, notification of change of address, or other matters should contact:
Nevada Agency and Trust Company
50 West Liberty, Suite 880
Reno, Nevada, 89501
(775) 322-0626 Telephone
(775) 332-5623 Fax
www.natco.org
CytoGenix, Inc. is a Houston-based biopharmaceutical company pioneering the new field of gene based medicine and is focused on developing innovative vaccines and therapeutic products using its three proprietary technology platforms: synDNATM non-bacterial production methodology, single stranded DNA (ssDNA) expression, and oligonucleotide based anti-bacterial technologies. CytoGenix currently holds 13 granted patents and 57 international or US pending patent applications claiming methods and materials in connection with these platform technologies.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the Company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |